Steven Nichtberger, Cabaletta Bio CEO
May 18, 2023 07:07 AM EDT
Financing

Ca­balet­ta lands $84M from stock sale af­ter FDA clears INDs for CD19 CAR-T in au­toim­mune dis­eases

Amber Tong

With the FDA’s clear­ance to put its CD19 CAR-T in­to two clin­i­cal tri­als for au­toim­mune dis­eases, Ca­balet­ta Bio has scored

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

MIT sci­en­tists’ AI mod­el one-ups Al­phaFold 3, takes on ‘fun­da­men­tal is­sue’ in drug R&D

EMA con­sid­ers se­ri­ous eye con­di­tion a ‘very rare’ side ef­fect of semaglu­tide 

Biotech ranks as Chi­na’s best shot to sur­pass US in emerg­ing tech, re­port finds

At a cross­roads, biotechs are pass­ing on re­verse merg­ers in 2025

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times